Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferons and neurologic diseases].

P Vermersch1, J de Seze, D Ferriby

  • 1Clinique neurologique, hôpital R.-Salengro, CHU de Lille, 59037 Lille, France. pvermersch@chru-lille.fr

La Revue De Medecine Interne
|December 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Revue neurologique·2025
Same author

Teriflunomide, cognition and MRI: A longitudinal study.

Multiple sclerosis and related disorders·2024
Same author

Clinical applications of deep learning in neuroinflammatory diseases: A scoping review.

Revue neurologique·2024
Same author

Real-life after sacral nerve modulation implantation: Rate, reasons, and risk factors for mid-term follow-up discontinuation.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Standardized one-day evaluation before urinary reconstructive surgery for neurogenic lower urinary tract dysfunction: Feasibility and impact on surgical strategy and care pathway.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
Same journal

[Patient similarity: When the internist's reasoning meets artificial intelligence].

La Revue de medecine interne·2026
Same journal

[Satisfaction of healthcare professionals within a multidisciplinary day-hospitalization for patients with systemic autoimmune rare disease].

La Revue de medecine interne·2026
See all related articles

Beta interferons are a first-line treatment for relapsing-remitting multiple sclerosis, reducing relapses and disability progression. Early intervention with beta interferons is recommended, with combination therapies considered for treatment failures.

Area of Science:

  • Neurology
  • Immunology

Context:

  • Interferons are primarily used therapeutically in neurology for multiple sclerosis (MS).
  • Beta interferons (IFN-β) are established as a first-line treatment for relapsing-remitting MS (RRMS).

Purpose:

  • To review the efficacy and application of beta interferons in treating multiple sclerosis.
  • To discuss the role of early intervention and potential combination strategies in MS management.

Summary:

  • Beta interferons demonstrate efficacy in reducing relapse rates (approx. 3%) and delaying disability progression in RRMS.
  • IFN-β positively impacts MRI-detected brain lesions, supporting early treatment initiation.
  • The efficacy in secondary progressive MS is debated, though dose-response relationships may exist.

Related Experiment Videos

Impact:

  • Early IFN-β treatment is suggested following the first demyelinating episode in at-risk individuals.
  • Combination therapies involving beta interferons may be necessary for treatment-resistant MS.
  • Limited success has been observed when interferons were tested in other neuroinflammatory conditions like chronic inflammatory demyelinating neuropathies.